Highlights

  • Neuren Pharmaceuticals announced a US Notice of Allowance related to trofinetide dosing.
  • The Patent application covers weight-banded dosing methods for Rett syndrome treatment.
  • The company expects potential US protection to extend to March 2041 if granted.
  • Trofinetide is marketed as DAYBUE through Neuren’s licensing partner.
  • The announcement does not provide financial forecasts or Revenue estimates linked to the patent.

Neuren Pharmaceuticals Limited (ASX:NEU) is a biotechnology company focused on developing therapies for neurodevelopmental disorders. The company’s latest announcement relates to a US patent allowance connected with trofinetide, a treatment developed for Rett syndrome, and the potential extension of intellectual property protection associated with the medicine.

US Patent Allowance Details

Neuren announced that its licensee Acadia Pharmaceuticals received a Notice of Allowance from the United States Patent and Trademark Office for a patent application covering methods and compositions for the treatment of Rett syndrome.

The application relates to weight-banded dosing of trofinetide. Neuren stated that, if granted, the resulting patent protection is expected to extend to 28 March 2041, including six months of paediatric exclusivity.

Trofinetide and Licensing Arrangement

Trofinetide is marketed as DAYBUE oral solution and DAYBUE STIX powder. According to the company, the treatment has received approval from the US Food and Drug Administration for treating Rett syndrome in patients aged two years and older, including adults.

Neuren licenses trofinetide exclusively to Acadia Pharmaceuticals for worldwide development and commercialisation. Under this arrangement, Acadia is responsible for Marketing the medicine and received the patent office notification.

Existing Patent Protection and Future Steps

The company stated that the existing method-of-use patent for trofinetide expires in July 2036. The newly allowed application would provide a later expected expiry date if the patent is formally granted.

A Notice of Allowance indicates that the patent application has been determined to be allowable, but it does not represent the final granting of the patent. Additional administrative steps are required before patent issuance.

Broader Development Pipeline

Neuren also develops NNZ-2591, also known as ercanetide, for neurodevelopmental disorders. The company stated that this programme is currently in Phase 3 trials for Phelan-McDermid syndrome.

The announcement focused on the trofinetide patent update and did not provide new information on NNZ-2591 development activities or financial outcomes.

Key Insights

Neuren Pharmaceuticals’ latest announcement highlights an intellectual property milestone related to trofinetide. The potential extension of US patent protection depends on the application being formally granted, while the commercial impact of any extended protection will depend on future market conditions, regulatory developments and product performance.